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ABSTRACT
Background: There is a lack of knowledge on the association between daily physical activity and
lung function in patients with asthma.
Objective: This study aims to examine the association between daily physical activity and asthma
control, lung function, and lung function decline in patients with adult-onset asthma.
Design: This study is part of Seinäjoki Adult Asthma Study (SAAS), where 201 patients were
followed for 12 years after asthma diagnosis. Daily physical activity was assessed at follow-up by a
structured questionnaire and used to classify the population into subgroups of low (≤240 min) or
high (>240 min) physical activity. Three spirometry evaluation points were used: 1. diagnosis, 2.
the maximum lung function during the first 2.5 years after diagnosis (Max0-2.5), 3. follow-up at
12 years.
Results: High physical activity group had slower annual FEV1 (p<0.001) and FVC
(p<0.018) decline. Additionally, the high physical activity group had higher FEV1 values at
follow-up, and higher FEV1/FVC ratios at follow-up and diagnosis. There was no difference in
BMI, smoking, medication, or frequency of physical exercise between high and low physical
activity groups. Differences remained significant after adjustments for possible confounding
factors.
Conclusion: This is the first demonstration of an association between long-term FEV1 decline and
daily physical activity in clinical asthma. Low physical activity is independently associated with
faster decline in lung function. Daily physical activity should be recommended in treatment
guidelines in asthma.
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Introduction
Physical activity has been shown to have several health
benefits such as reducing the risk of ischemic heart dis-
ease, diabetes and colon cancer [1]. Most of the previous
research on physical activity has focused on moderate to
vigorous intensity activities such as running whereas less
is known on the low intensity everyday movement which
constitutes the majority of the physical activity accumu-
lated throughout the day. A structured exercise program
is often used as an intervention in studies, but the rest of
the daily physical activity is frequently overlooked.
Caspersen et al. [2] defined physical activity as ‘any bodily
movement produced by skeletal muscles that requires
energy expenditure’ and physical exercise as ‘a subset of
physical activity that is planned, structured, and repetitive
and has as a final or an intermediate objective the
improvement or maintenance of physical fitness’. These
definitions are currently used by the World Health
Organization (WHO) [3]. Physical activity thus includes
all human movement whereas physical exercise is high or
moderate intensity movement conducted with a purpose
for shorter periods of time. It is important to differentiate
between these two terms since different intensities of
physical activity have different effects on the body [4].
Thus, it is crucial to study physical activity as a whole
instead of focusing solely on the moderate to vigorous
intensity activities. In the context of this study the term
physical activity includes all physical activities from loun-
ging around the shopping mall to going for a jog and the
term exercise only means moderate to high intensity
activities.
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Asthma is a chronic inflammatory disease of the
airways. Over the past years researchers have identified
several phenotypes of asthma revealing the heterogene-
ity of the disease [5,6]. Age of onset of asthma has been
found as a key differentiating factor between the phe-
notypes. It has been shown recently that the adult-
onset phenotypes differ vastly from childhood-onset
asthma [5,6]. Childhood asthma is often an atopic
disease characterized by high numbers of bronchial
eosinophils and high serum levels of IgE with a good
response to glucocorticoid treatment. In contrast,
patients with disease onset at adulthood have often
more severe asthma that rarely remits [7]. Recently,
asthma diagnosed at adult-age has been shown to con-
stitute a majority among all new cases of asthma [8],
and it seems that several lifestyle factors such as cigar-
ette smoking and obesity are major factors in adult-
onset asthma [6,9]. Since the concept of adult-onset
phenotypes is rather new, only few studies exist on it
and there is no clear consensus on the best therapy for
these patients. Occasionally, adult-onset asthma may
also be difficult to distinguish from chronic obstructive
pulmonary disease (COPD) due to the overlap of
symptoms and risk factors [10].
Physical exercise has been shown to be a beneficial
factor in the control of asthma [11]. Physical exercise
reduces systemic and bronchial inflammation, and
increases maximal oxygen uptake [12,13]. Most
research on daily physical activity in asthma focuses
either on the risk of developing asthma or exercise-
induced bronchoconstriction. There are no published
long-term studies on daily physical activity in patients
with clinical asthma. Daily physical activity has been
studied extensively in COPD where higher levels of
physical activity decelerate lung function decline and
improve the quality of life [14,15]. Previous reports
have shown that high physical activity is associated
with better lung function, slower lung function decline,
and lower mortality also in the general population
[16,17]. However, so far there are no previous studies
on the association between physical activity and lung
function change over several years in patients with
clinical asthma.
The aim of this study was to examine the association
between daily physical activity and asthma control,
lung function, or lung function decline in patients
with adult-onset asthma.
Materials and methods
Study population and design
Seinäjoki Adult Asthma Study (SAAS) is a single-center
(Department of Respiratory Medicine, Seinäjoki Central
Hospital, Seinäjoki, Finland) 12-year follow-up study. The
study protocol and the inclusion and exclusion criteria
have been previously published [18]. Study population
consists of 260 consecutive patients who were diagnosed
with adult-onset asthma in 1999–2002 by a respiratory
physician (Figure 1). Patients were recruited from the
diagnostic visit. Diagnosis was based on typical symptoms,
and it was confirmed by objective lung function measure-
ments [18]. Smokers (current or ex-) and patients with co-
morbidities were included in the study. The patients were
treated and monitored according to Finnish Asthma
Program guidelines [19] either in the specialized care or
in primary care. The collection of research data has been
previously reported [7,9,10,20]. At diagnosis, data was
collected on lung function, blood eosinophils, the initial
pharmacotherapy, and asthma symptoms by Airways
Questionnaire 20 (AQ20) [21]. Atopy was defined as at
least one positive response (≥3 mm) in skin prick toward
common aeroallergens. After 12 years patients were
invited to a re-evaluation (2012–2013), and 201 (77%)
Figure 1. Flow chart of the study.
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patients arrived to the follow-up visit. At follow-up infor-
mation was collected on asthma status, medication, and
co-morbidities by structured questionnaire. Lung function,
blood eosinophils and neutrophils, IgE levels, fraction of
exhaled nitric oxide (FeNO), interleukin-6 (IL-6), and high
sensitivity C-reactive protein (hsCRP) were measured.
Patients also filled Asthma Control Test (ACT) [22],
AQ20, and a structured lifestyle questionnaire.
Specifically trained research nurse reviewed all question-
naires with the patients to limit misunderstandings. A
written informed consent was obtained to a study protocol
approved by the Ethics committee of Tampere University
Hospital, Tampere, Finland (R12122).
Determination of physical activity
The level of physical activity was assessed at follow-up by a
structured questionnaire. Overall daily physical activity
was assessed by an open question: ‘How many minutes
in a day do you spend moving?’ After pre-evaluation,
patients were divided into high and low daily physical
activity groups. Cut off-point was established at 240 min
of daily physical activity per day. The frequency of physical
exercise was estimated by the following question: ‘How
often do you take part in leisure time activities for at least
half an hour so that you are at least somewhat breathless
and sweaty?’ This question had eight choices ranging from
never to everyday. In this study, physical activity time and
physical exercise frequency are assessed as their own vari-
ables and are not to be confused with each other.
Determination of lung function
Lung function was assessed using a spirometer (Vmax
Encore 22, Viasys Healthcare, Palm Springs, CA, USA)
according to international recommendations [23] and
Finnish reference values [24]. Post-bronchodilator mea-
surements were taken 15 min after inhalation of salbuta-
mol (400 µg). After the initiation of asthma therapy, only
pre-bronchodilator spirometry was measured on most of
the patients, and therefore we evaluated the changes in
pre-bronchodilator spirometry values throughout the
study. Lung function measurement points were: (1) base-
line (i.e. time of asthma diagnosis), (2) the maximum
lung function (Max0-2.5) during the first 2.5 years after
diagnosis (i.e. after start of anti-inflammatory therapy)
based on the highest pre-bronchodilator FEV1% pre-
dicted, and (3) after 12 years of follow-up (Figure 2) [9].
Statistical analyses
Continuous data is expressed as mean (SD) for variables
with normal distribution and as median and interquar-
tile range for variables with skewed distribution. To
assess differences between high and low physical activity
groups, we used Mann-Whitney test for continuous
variables with skewed distributions, independent sam-
ples t-test for continuous variables with normal distri-
bution, and Chi-Square test for categorized variables.
Multiple linear regression analysis was performed to
analyze factors associated with FEV1 decline from point
of Max0-2.5 to the follow-up visit. To avoid multicollinear-
ity, explanatory variables were checked for strong (>0.7)
mutual correlation. Patients whose BMI differed over 3 SD
(n = 4) or whose FEV1 decline differed over 3.3 SD (n = 3)
from mean were removed from the linear regression ana-
lysis as outliers to ensure homoscedasticity. Forward, back-
ward and enter methods were used to improve model fit.
Statistical analyses were performed using SPSS software,
version 23 (IBM SPSS, Chicago, IL, USA). A p-value <0.05
was regarded as statistically significant.
Results
Patient characteristics
Characteristics of the patients who attended the follow-
up visit are shown at eTable 1. The median age of the
study population was 45 (SD 14) years at diagnosis and
58% were females. Of the patients, 53% had smoking
history. The proportion of daily inhaled glucocorticoid
users was 8% at diagnosis, 96% at Max0-2.5, and 76% at
Figure 2. Representation of the three lung function measurement points.
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follow-up. Patients reported a median of 360 (inter-
quartile range 180–540) min of daily physical activity.
When patients were divided into two groups based
on the level of daily physical activity (≤240 min vs.
>240 min) the group with the higher amount of phy-
sical activity was younger and they had earlier asthma-
onset (Table 1). The high physical activity group
included a higher percentage of females than the low
physical activity group. The high physical activity
group also included less patients with post-bronchodi-
lator FEV1/FVC<0.7 and a history of smoking for at
least 10 pack years (Table 1), characteristics which may
indicate an asthma-COPD overlap syndrome (ACOS)
[25]. Notably, there were no differences in BMI, smok-
ing status, medication for asthma, or frequency of
physical exercise between the two groups (Table 1).
Association between physical activity and lung
function
Lung function was significantly different between the high
and low physical activity groups. The high physical activity
group had higher pre- and post-bronchodilator FEV1-
values at follow-up (Table 2) but only pre-bronchodilator
FEV1-value was higher at diagnosis (eTable 2). FEV1/FVC-
ratios (pre- and post-BD) were significantly different at
diagnosis and at follow-up between the groups (Table 2,
eTable 2). After removal of patients with post-bronchodi-
lator FEV1/FVC<0.7 and a smoking history of at least 10
pack years (eTable 3), which may indicate the presence of
ACOS [25], post-bronchodilator FEV1/FVC-ratio at fol-
low-up remained significantly lower in the low activity
group (p = 0.032). This indicates that possible ACOS is
not explaining the results.
Association between physical activity and lung
function decline
When evaluating lung function decline from Max0-2.5
to follow-up visit in the high and low physical activ-
ity groups, a more rapid decline in FEV1 (ml and %
of reference) and FVC (ml) in the group with less
daily physical activity was observed (Table 3,
Figure 3). The measurement point of Max0-2.5 was
chosen because the patients had untreated asthma at
diagnosis, and their lung function improved signifi-
cantly during the following months due to start of
asthma therapy. Therefore, comparisons between
diagnostic and follow-up values would be compari-
sons between untreated and treated asthma. The
differences between the groups remained significant
when patients with post-bronchodilator FEV1/
FVC<0.7 and a smoking history of at least 10 pack
years were removed from the cohort (eTable 4). The
frequency of physical exercise had no effect on lung
function decline (data not shown).
Association between daily physical activity, asthma
control, and symptoms of asthma
The high and low physical activity groups had no
significant difference in asthma control or symptoms
when measured by using AQ20 overall scores
(eTable 5) or ACT (Table 4). However, when analyz-
ing the separate questions in ACT and AQ20 ques-
tionnaires, differences were found. The low physical
activity group had more shortness of breath and a
worse self-perceived asthma control (ACT questions
2 and 5; Table 4). In AQ20 questionnaire the low
physical activity group reported more breathlessness
in questions 3 (breathlessness during gardening)
(p = 0.002), 13 (breathlessness during housework)
(p = 0.020) and 10 (difficulties in getting around
the house due to chest problems) (p = 0.028)
(eTable 5).
Table 1. Basic subject characteristics by physical activity groups.
≤240 min of
physical
activity/day
>240 min of
physical
activity/day p-value*
Number of patients 74 127
Age (years) 61 (13) 57 (14) 0.036
Age of onset (years) 49 (13) 44 (14) 0.029
Males 39 (53%) 45 (35%) 0.018
Duration of daily physical
activity (min)
135 (90–180) 480 (360–600) <0.001
Patients exercising at least
3 times per week
43 (58%) 69 (54%) 0.660
BMI (kg/m2) 28.7 (5.2) 28.4 (5.8) 0.807
Ex or current smoker 38 (51%) 68 (54%) 0.772
Pack years (of ex- and
current smokers)
20 (10–32) 15 (4–27) 0.067
Post-brochodilator FEV1/
FVC <0.7 and at least
10 pack years
17 (24%) 16 (13%) 0.050
Patients with at least one
co-morbidity
51 (70%) 76 (60%) 0.172
Number of co-morbidities,
COPD included
1 (0–3) 1 (0–2) 0.091
Daily ICS users 60 (81%) 93 (73%) 0.233
ICS dose (μg budesonide
equivalent)
800 (400–
1000)
800 (280–
1000)
0.393
Patients who received oral
corticosteroids
30 (41%) 35 (28%) 0.062
Daily add-on medication
(includes LABA)
39 (53%) 62 (49%) 0.661
Atopy 18 (27%) 49 (42%) 0.055
*Statistical significances were evaluated using Mann-Whitney test, inde-
pendent samples t-test or Chi-square test, respectively. Results are dis-
played as median (interquartile range), mean (SD), or n (%). BMI: body
mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; COPD: chronic obstructive pulmonary disease; ICS: inhaled
corticosteroid; LABA: long acting beta-adrenoceptor agonist.
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Association of daily physical activity, systemic and
airway inflammatory parameters
Blood neutrophils, eosinophils, FeNO, IL-6, and
hsCRP were measured. No differences were
observed in any of these biomarkers of inflamma-
tion between the high and low activity groups
(eTable 6).
Factors associated with lung function decline
To assess whether lower physical activity remains
statistically significant factor associated with more
rapid lung function decline in patients with adult-
Figure 3. Changes in mean Pre-BD FEV1 (mL) during 12 years of follow-up in the groups of <240 or ≥240 min of daily physical
activity.
Table 2. Lung function at follow-up by physical activity groups.
≤240 min of physical activity/day >240 min of physical activity/day p-value*
FVC (%ref) pre-BD 95 (16) 98 (15) 0,222
FVC (%ref) post-BD 97 (16) 99 (14) 0,269
FEV1 (%ref) pre-BD 81 (19) 88 (16) 0,004
FEV1 (%ref) post-BD 84 (18) 91 (16) 0,004
FEV1/FVC pre-BD 0.71 (0.63–0.78) 0.75 (0.69–0.79) 0,002
FEV1/FVC post-BD 0.72 (0.65–0.79) 0.77 (0.71–0.81) 0,001
*Statistical significances were evaluated using Mann-Whitney test or independent samples t-test. Results are displayed as median (interquartile range) or
mean (SD).FVC: forced vital capacity; BD: bronchodilator; FEV1: forced expiratory volume in 1 s.
Table 3. Annual pre-BD lung function decline from Max0-2.5 to follow-up by physical activity group.
≤240 min of physical activity/day >240 min of physical activity/day p-value*
ΔFVC/year, pre-BD (ml) −43.6 (42.1) −29.3 (39.7) 0.018
ΔFVC/year, pre-BD (%) −0.12 (1.14) 0.03 (0.95) 0.325
ΔFEV1/year, pre-BD (ml) −58.8 (37.3) −41.4 (34.2) 0.001
ΔFEV1/year, pre-BD (%) −0.83 (1.13) −0.39 (0.97) 0.005
ΔFEV1/ΔFVC -ratio/year, pre-BD −0.0052 (−0.0101 to −0.0019) −0.0041 (−0.0075 to −0.0016) 0.062
*Statistical significances were evaluated using Mann-Whitney test or independent samples t-test. Results are displayed as median (interquartile range) or
mean (SD). FVC: forced vital capacity, BD: bronchodilator, FEV1: forced expiratory volume in 1 s.
Table 4. Asthma control and symptoms at follow-up.
≤240 min of
physical
activity/day
>240 min of
physical
activity/day p-value*
Uncontrolled asthma** 27 (36.5) 32 (25.2) 0.234
ACT score at follow-up 22 (17–24) 22 (20–24) 0.159
ACT Q2 shortness of breath
at least 3–6 times/week
22 (29.7) 16 (12.6) 0.005
ACT Q5 asthma somewhat
controlled, poorly
controlled, not at all
controlled
25 (33.8) 25 (19.7) 0.029
*Statistical significances were evaluated using Chi-square test or Mann-
Whitney test. Results are displayed as n (%) or median (interquartile
range). ACT: asthma control test.
**As assessed according to GINA 2010 as previously described [18].
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onset asthma after adjusting for age, sex, smoking,
BMI, atopy, and use of inhaled glucocorticoid, we
carried out multiple linear regression analysis. Daily
physical activity ≤240 min remained statistically sig-
nificantly associated with more rapid decline in FEV1
in adjusted analysis. Other explanatory factors of
faster lung function decline were sex (male), atopy,
and a higher BMI. (Table 5) During the building of
this linear regression model other variables were
tried but inclusion of these variables gave the best
model.
Discussion
The aim of this study was to examine the significance of
daily physical activity in adult-onset asthma. Our data
indicates that higher daily physical activity is associated
with slower decline in lung function even when adjust-
ing for sex, age, BMI, atopy, medication, and smoking.
High and low physical activity groups in this study had
no difference in BMI, smoking, medication, interleukin-
6, hs-CRP, IgE, blood neutrophil or eosinophil counts,
FeNO levels, or the frequency of exercise. The fact that
there was no difference in BMI was surprising since high
BMI has been linked to low physical activity [26]. The
low cut-off point of 240 min could explain the absence
of differences in inflammatory markers. Also, differ-
ences in dietary habits and energy expenditure can
explain the absence of BMI difference. High physical
activity group had a higher percentage of females,
which suggests that females do more low intensity phy-
sical activities in this set up. There was no difference in
biomarkers of systemic inflammation between the
groups with lower and higher daily physical activity
even though it has been shown that regular physical
exercise can reduce systemic inflammation [27]. The
frequency of exercise was not associated with lung func-
tion decline in this study, which was expected since
there were no significant differences in the frequency
of exercise between the two groups of high and low
levels of daily physical activity.
To our knowledge this study is the first to examine
the association between daily physical activity and
FEV1 decline in clinical asthma. Our finding is sup-
ported by a similar association recently reported
between leisure time activity and lung function change
in persons having self-reported asthma in a population
based cohort of the Nord-Trøndelag Health Study [28].
Our study has several strengths. All asthmatics were
carefully diagnosed by a respiratory physician, and the
diagnosis was verified with spirometry, serial peak flow
measures, or measures of bronchial hyperreactivity.
Most patients were treated with at least inhaled gluco-
corticoids between Max0-2.5 and follow-up. Smokers
and patients with co-morbidities were not excluded
making this a real life study. During 1999–2002 a
considerable proportion of novel asthma diagnoses in
the region were made at Seinäjoki Central Hospital and
>94% of the patients obtaining diagnosis of asthma in
this hospital at the study period took part in the study
[18]. Therefore, this study population well represents a
primary care population with asthma. However,
patients with very mild or seasonal asthma may have
been excluded since patients had to fill the strict lung
function criteria [18].
The cut-off point for high and low levels of daily
physical activity in this study was chosen at 240 min of
physical activity per day. The cut-off point divided the
cohort into the lowest one third against the two highest
thirds. The patients were made well aware of what the
question meant so that all misunderstandings could be
minimized. Patients in this study had a median of
360 min of daily physical activity, which is similar to
levels measured by accelerometers in patients with
chronic diseases (range 308–395 min) [29–31]. The
cut-off point of 240 min of physical activity is a rela-
tively low level considering that even older care home
residents in the UK [32] and aged (73–98 year-olds)
Icelandic people [33] accumulated 122–190 min of
daily physical activity. The cut-off point was intention-
ally set at this relatively low level to allow examinations
of the effects of very low amounts of physical activity.
The most significant limitation of this study is the
absence of spirometric post-bronchodilator values at
Max0-2.5. This is due to the fact that the patients were
treated according to the Finnish asthma guidelines
where systematic recording of post-bronchodilatory
values was not recommended at that time. Even though
the patients’ estimates on their physical activity are close
to measured values on similar cohorts, it would have
been optimal to record daily physical activity using
accelerometers. In addition, physical activity was
Table 5. Association of explanatory factors with lung function
decline from Max0-2.5 to follow-up in multiple linear regression.
Variable
Estimate
(Δml)
95% Confidence
Interval p-value
(Constant) −22.39 −69.16 to 24.39 0.346
Physical activity over
240 min/day
17.90 8.00 to 27.80 <0.001
Sex (female) 13.12 3.08 to 23.16 0.011
Age at follow-up −0.23 −0.59 to 0.13 0.209
BMI at follow-up −1.01 −2.02 to −0.01 0.048
Not a daily ICS user at
follow-up
1.40 −10.15 to 12.95 0.811
Atopy −11.38 −21.72 to −1.04 0.031
Ever smoker at follow-up −1.97 −11.70 to 7.76 0.690
n = 173 (outliers: n = 7, missing data: n = 21), BMI: body mass index, ICS:
inhaled corticosteroid.
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assessed only at follow-up visit. However, it has been
shown that most of our health related habits are formed
during childhood or early adulthood and decline slowly
or remain constant during adulthood. Significant
changes in health related habits are unlikely to happen
without a comprehensive lifestyle intervention [34,35].
Therefore, it can be assumed that the high physical
activity group had higher activity levels also at diagnosis.
Similar findings to our study have been previously
obtained in patients with COPD and in general popu-
lation [14,16]. During an 11-year follow-up in patients
with COPD, low physical activity group had a faster
decline in lung function (−4.8 ml/year faster drop of
FEV1, −7.7 ml/year faster drop of FVC) when com-
pared to high physical activity group [14]. Slower FEV1
decline with higher physical activity has been detected
on general population also [16]. In our study FEV1
declined 17.4 ml/year faster, and FVC declined
14.3 ml/year faster in the low activity group. Sex
(male), high frequency of disease exacerbations, old
age, absence of glucocorticoid treatment, and smoking
have been found to accelerate FEV1 decline in asth-
matics [9,36,37]. After adjusting for these factors with
multiple linear regression analysis, the association of
physical activity with FEV1 decline remained signifi-
cant. Exacerbations were not included in the linear
regression, but there was no difference in the propor-
tion of those patients receiving oral corticosteroid
treatment during the follow-up period between the
physical activity groups suggesting that there was no
difference in exacerbations.
The findings are clinically significant, since remis-
sion rate in adult onset asthma is low [7] and most
patients suffer from asthma for decades. The linearity
of the effect of physical activity on lung function
remains unclear. We found one daily physical activity
intervention study in pediatric patients with asthma
[38], and no change in FEV1 was registered during a
one-week follow-up. Also, in a recent cross-sectional
study [39] daily physical activity had no effect on
spirometric values of healthy adolescents. In patients
with childhood-onset asthma there is a positive asso-
ciation between physical activity and lung function
during a 3 week period [40], but this could be due to
several acute bronchodilations or patients uncon-
sciously adjusting their daily activity according to
their lung function earlier that day. In light of this
evidence it seems likely that daily physical activity
does not cause long term improvements in FEV1, but
that it slows down FEV1 decline. However, as the data
on physical activity was collected at follow-up visit, the
relation between lung function decline and physical
activity level may also reflect that those with more
rapid lung function decline are prone to decrease
their level of physical activity.
Conclusion
This study highlights the importance of active lifestyle
and the perils of sedentary habits. Modern physical
activity guidelines focus on higher intensity activities,
but it would be important to include low intensity
activities to these guidelines for more holistic approach.
More studies with a precise analysis of the activity
intensity are needed to further explore the effect of
physical activity on patients with asthma.
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